{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-22-027263","form_type":"8-K","ticker":"RVPH","cik":"0001742927","company_name":"REVIVA PHARMACEUTICALS HOLDINGS, INC.","filed_at":"2022-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.949600+00:00","generated_at":"2026-06-21T20:45:21.657084+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Reviva Q3 net loss $3.5M; cash $23.2M; Phase 3 enrollment >30%, topline mid-2023","bullets":["Net loss of $3.5M ($0.18 per share) for Q3 2022 vs $2.3M ($0.12) in Q3 2021.","Cash $23.2M as of Sep 30, 2022, down from $29.7M at Dec 31, 2021; sufficient through Nov 2023.","Phase 3 RECOVER trial for brilaroxazine enrolled >30% in US; topline data expected mid-2023.","Announced $8.5M registered direct offering in September 2022.","Exploring non-dilutive financing for expansion into bipolar, MDD, ADHD, PAH, IPF indications."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-22-027263","json":"https://secwatch.observer/filing/0001437749-22-027263.json","markdown":"https://secwatch.observer/filing/0001437749-22-027263.md","text":"https://secwatch.observer/filing/0001437749-22-027263.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1742927/000143774922027263/0001437749-22-027263-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1742927/000143774922027263/rvph20221111_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T20:45:21.657084+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"84f4add3a4004c6ed7346fb1072d351e29f5398b","claim":"REVIVA PHARMACEUTICALS HOLDINGS, INC. reported the nine months ended September 30, 2022 results: net income approximately $16.2 million, EPS ($0.87) per share.","evidence_excerpt":"The Company reported a net loss of approximately $16.2 million, or ($0.87) per share, for the nine months ended September 30, 2022, compared to a net loss of approximately $4.8 million, or ($0.36) per share, for the same period in 2021.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1742927/000143774922027263/0001437749-22-027263-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the nine months ended September 30, 2022"},{"label":"Net income","value":"approximately $16.2 million"},{"label":"EPS","value":"($0.87) per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"c219c95721f80de9fe3c680837126fd973f170e4","claim":"REVIVA PHARMACEUTICALS HOLDINGS, INC. reported the three months ended September 30, 2022 results: net income approximately $3.5 million, EPS ($0.18) per share.","evidence_excerpt":"The Company reported a net loss of approximately $3.5 million, or ($0.18) per share, for the three months ended September 30, 2022, compared to a net loss of approximately $2.3 million, or ($0.12) per share, for the same period in 2021.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1742927/000143774922027263/0001437749-22-027263-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months ended September 30, 2022"},{"label":"Net income","value":"approximately $3.5 million"},{"label":"EPS","value":"($0.18) per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}